California public workers could get weight-loss drug coverage

In California, public employees and retirees could be offered an optional weight-loss benefit that covers GLP-1 drugs, nutrition counseling and other obesity treatments. Sen. Laura Richardson’s SB 1089 would require the plans to provide that coverage from Jan. 1, 2027, through Jan. 1, 2032.

The benefit would be optional for workers, but the plans would have to make it available. It would cover semaglutide, GLP-1 receptor agonist drugs, GIP+GLP-1 tirzepatide and future chronic weight-disease products in forms that include pens, vial injections, pills and patches.

A benefit with a drug list

The bill is not written as a one-size-fits-all mandate. It sets the benefit out as a choice a public plan must offer, which matters because coverage is often where a treatment class becomes part of ordinary care instead of a private luxury.

Available vote records show the bill advanced without recorded no votes.

The state wants to shop for everyone

SB 1089 also uses the California Health and Human Services Agency as the price setter. The agency would have to make the medications available to state and local government employers at the costs tied to a Public Employees’ Retirement System health benefit plan or contract, building on a drug-partnership model the state has already used for other treatments.

The bigger question is whether that same pricing could go beyond government workers. The bill would require the agency to decide whether chronic weight-disease medications should be made available to all Californians at the same PERS-plan cost levels, turning public coverage into a test case for wider access.

That is the policy gamble at the center of the proposal: if California can buy the drugs at a lower price for its own plans, it may be able to use that leverage to push the cost down for more people. The bill does not guarantee that outcome. It only builds the mechanism to try.